NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

Authors:

Abstract
No abstract available
Funding Information
  • University of Pennsylvania (SCR_010035)
  • Cancer Research Foundation
  • Pediatric Cancer Research Foundation
  • Leukemia and Lymphoma Society
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (F32 HL156600, R01HL142782, R01HL166184)
  • University of Chicago (SCR_019196, SCR_017760)
  • National Cancer Institute (R01CA231880, T32CA009594)

This publication has 57 references indexed in Scilit: